Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer [Yahoo! Finance]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Yahoo! Finance
Inc. (NASDAQ: MLYS ) is one of the best new stocks to invest in according to hedge funds. On March 24, Mineralys Therapeutics appointed Jeffrey A. Munsie as Chief Legal Officer to oversee the company's legal and compliance functions. Munsie brings 25 years of biopharmaceutical experience to the role, having previously served in leadership positions at Orbital Therapeutics, Concert Pharmaceuticals, and Merrimack Pharmaceuticals. His background spans the full drug development lifecycle, from preclinical stages through commercialization, which the company views as essential for its next phase of growth. In his new role, Munsie will provide strategic counsel as Mineralys Therapeutics Inc. (NASDAQ:MLYS) advances its lead candidate, lorundrostat, which targets hypertension and related conditions like chronic kidney disease and obstructive sleep apnea. CEO Jon Congleton highlighted Munsie's proven track record in handling intellectual property strategy, transactions, and compliance as a key
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026GlobeNewswire
- Mineralys Therapeutics (MLYS) is now covered by TD Cowen. They set a "buy" rating on the stock.MarketBeat
- Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal OfficerGlobeNewswire
MLYS
Earnings
- 3/12/26 - Beat
MLYS
Sec Filings
- 4/21/26 - Form 4
- 4/17/26 - Form 144
- 4/15/26 - Form 4
- MLYS's page on the SEC website